Abstract
Background Chronic heart failure (HF) coexist with chronic obstructive pulmonary disease (COPD) in approximately 25% of patients and is associated with worse outcomes. Lung ultrasound (LUS) is a validated technique to diagnose pulmonary congestion by detecting vertical lung artifacts, B-lines. Pulmonary inflammation is also associated with B-lines, but little is known about LUS in patients with acute exacerbation of COPD (AECOPD).
Aims To assess the feasibility of LUS to detect concurrent acute HF in AECOPD and examine the associations between B-lines, clinical parameters during hospitalization and re-hospitalizations and mortality.
Methods & results In a prospective cohort study 123 patients with AECOPD (age 75±9 years, 57 [46%] men) underwent 8-zone bedside LUS within 24h after admission. A positive LUS was defined by ≥3 B-lines in ≥2 zones bilaterally. A cardiologist committee blinded for LUS adjudicated whether concurrent HF was present (n=48, 39%). The median number of B-lines was 8 (IQR 5-13) and 16 (13%) patients had positive LUS. Positive LUS was associated with infiltrates on chest X-ray. The prevalence of positive LUS was similar with and without concurrent HF 8 (17%) vs 8 (11%), p=0.34, while the number of B-lines was higher in concurrent HF: median 10 (IQR 6–16) vs 7 (IQR 5-12) (p=0.03). The sensitivity and specificity for positive LUS to detect concurrent HF was 16.7% and 89.3%, respectively. Positive LUS was not associated with re-hospitalization and mortality: Adjusted HR 0.93 (0.49-1.75), p=0.81.
Conclusions LUS did not detect concurrent HF or predict risk in patients hospitalized with AECOPD.
Competing Interest Statement
This work was supported by grants from the Norwegian Society of Pulmonary Physicians, donated by Astra Zeneca. The sponsor had no input or contribution in the development of the research and manuscript.
Funding Statement
This work was supported by grants from the Norwegian Society of Pulmonary Physicians, donated by Astra Zeneca.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Helse Sorost gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared last author
Data Availability
All data produced in the present study are available upon reasonable request to the authors